文献速递外周动脉疾病

新型西罗莫司涂层球囊治疗股腘动脉病变的短期与中期疗效及安全性:单臂Meta分析

Short- and Mid-Term Efficacy and Safety of Novel Sirolimus-Coated Balloon for Treatment of Femoropopliteal Lesions: A Single-Arm Meta-Analysis.
PubMed 文献 · J Endovasc Ther · 2025-04-21

该单臂Meta分析纳入5项单臂试验,评估新型西罗莫司涂层球囊(SCB)治疗股腘动脉病变的疗效与安全性。6个月随访时汇总一期通畅率92%、免于靶病变血运重建率96%(异质性I²=0%),12个月随访时分别为87%和96%,死亡汇总发生率6个月为1%、12个月为4%。作者认为SCB有效且安全,可能成为股腘动脉病变的替代选择,但仍需进一步研究。

要点

  • 6个月随访汇总一期通畅率92%,免于靶病变血运重建率96%,异质性I²=0%。
  • 12个月随访汇总一期通畅率87%,免于靶病变血运重建率96%,截肢率3%,死亡4%。
  • 作者认为新型SCB有效安全,可能成为股腘动脉病变的替代选择,但仍需进一步研究。

核心结论

  • 作者认为新型西罗莫司涂层球囊治疗股腘动脉病变有效且安全,可能成为股腘动脉病变的替代选择,但仍需进一步研究。

研究设计与样本

  • 检索PubMed、Scopus、Cochrane、Science Direct和Google Scholar数据库的单臂Meta分析,最终纳入5项单臂试验,采用ROBINS-I工具评估,使用RStudio的meta包进行单臂Meta分析。

主要发现

  • 6个月随访时汇总一期通畅率为92%,汇总免于靶病变血运重建率为96%,异质性I²=0%。
  • 6个月随访时汇总临床驱动靶血管血运重建发生率为1%,临床驱动靶病变血运重建发生率为2%,截肢率为3%,死亡发生率为1%。
  • 12个月随访时汇总一期通畅率为87%,汇总免于靶病变血运重建率为96%,截肢率为3%,死亡发生率为4%。

临床怎么用

  • 作者认为新型SCB可能成为股腘动脉病变的替代选择,有望成为有症状股腘动脉疾病患者的治疗选择,但仍需进一步研究。

局限性

  • 作者指出仍需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Over the years, paclitaxel-coated balloons (PCBs) have been considered a standard treatment for femoropopliteal (FP) lesions due to their higher efficacy compared to noncoated balloon angioplasty. However, some studies have raised concerns about a potential link between PCBs and increased long-term mortality. Although relatively new, sirolimus is studied as an alternative that could be safer and more efficacious. OBJECTIVE: This study aims to analyze the efficacy and safety of novel sirolimus-coated balloons (SCBs) for the treatment of femoropopliteal lesions. MATERIALS AND METHODS: A literature search was conducted across PubMed, Scopus, Cochrane, Science Direct, and Google Scholar databases. Five single-arm trials met the predefined eligibility criteria for inclusion and were assessed using the ROBINS-I tool. Data extraction was followed by single-arm meta-analysis in RStudio with meta package software. MAJOR FINDINGS: Overall, a total of 5 single-arm trials were included. During 6-month follow-ups, SCBs have proven to have a high primary patency rate (pooled: 92%) and high freedom to target lesion revascularization (TLR) rates (pooled: 96%) with no heterogeneity (I2 = 0%). In terms of safety, the pooled incidence of clinically driven-target vessel revascularization (CD-TVR) is 1%, while pooled clinically driven-target lesion revascularization (CD-TLR) rate is 2%, pooled amputation rate is 3%, and pooled incidence of mortality was 1%. During 12-month follow-ups, SCBs have high primary patency rate (pooled: 87%), high freedom to TLR rates (pooled: 96%), low amputation rate (pooled: 3%), and pooled incidence of mortality was 4%. CONCLUSION: Novel SCB is efficacious and safe in treating femoropopliteal lesions and thus could be a prompt alternative in treating FP lesions, although further studies are still needed. Hopefully, this method could be a treatment option for FP disease in symptomatic patients.Clinical ImpactSirolimus-coated balloons (SCBs) offer a promising alternative to paclitaxel-coated balloons (PCBs) for femoropopliteal lesions, demonstrating high efficacy with superior primary patency and low target lesion revascularization rates. The findings suggest SCBs may mitigate safety concerns associated with PCBs, potentially reducing long-term mortality risks. For clinicians, this innovation provides a safer, effective endovascular option, enhancing patient outcomes while maintaining procedural simplicity. With further validation, SCBs could redefine the standard of care for peripheral artery disease, ensuring optimal long-term vascular health with minimal complications.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Kalaij AGI, Benly ML, Aurora RG, et al. Short- and Mid-Term Efficacy and Safety of Novel Sirolimus-Coated Balloon for Treatment of Femoropopliteal Lesions: A Single-Arm Meta-Analysis. J Endovasc Ther. 2025. PMID: 40257241. doi:10.1177/15266028251328156

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。